Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seminoma 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Medulloblastoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hearing Loss 1Carcinoma 1

Interventions

Platinum 2veliparib 1trastuzumab deruxtecan 1sodium thiosulfate 1brodalumab 1Taxes 1Specimen Handling 1Psychiatric Nursing 1Physical Therapy Modalities 1Paclitaxel 1Neoadjuvant Therapy 1Methods 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Hearing 1Exercise 1Etoposide 1Cisplatin 1Carboplatin 1Bleomycin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Neoplasms × Hearing × 90 days × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡